Latest News

“[Epcoritamab/R2] is a good option for [patients] at first relapse or even further, even if they are very high risk,” said Benoit Tessoulin, MD, PhD.

In this retrospective cohort study, it was shown that acute pancreatitis hospitalizations occurred more frequently in patients with multiple myeloma who were older and more medically complex.

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission.

The MagUS magnetically-guided ultrasound biopsy technique enabled successful sentinel lymph node biopsy de-escalation in 7 patients who preferred axillary evaluation to surgical staging, with all pathology returning negative.

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.

In 42 patients with DCIS undergoing breast-conserving surgery, 71.4% had detectable disseminated cancer cells in bone marrow, with residual-risk DCISionRT score significantly correlated with higher DCC burden compared with low- and elevated-risk groups.

In this patient case, a 72-year-old male with primary malignant melanoma of the ascending colon received adjuvant therapy consisting of immunotherapy with PD-1 inhibitors.

In this Satellite Session, experts convened to discuss CAR T-cell candidacy among patients across a range of large B-cell lymphoma disease states.

According to Chinmay Jani, MD, a current goal in thoracic oncology is to turn lung cancer into a “chronic disease” where patients can live for decades.

Two teams of lung cancer experts face off to determine the optimal first-line treatment regimen in EGFR-mutated metastatic NSCLC.

This survey-based TIP study examines patient-perceived barriers to home recovery after mastectomy within a single ERAS-enabled hospital system, aiming to identify why patients decline same-day discharge despite being clinically eligible.

In 433 patients undergoing breast surgery, median VAS pain scores declined from 2 on day 1 to 0 by day 30, with severe pain in only 7.4% and opioid use in 2.5%, supporting nonopioid-based analgesic protocols.

ASCO Breakthrough 2026 spotlighted liquid biopsy, biomarkers, AI, and global equity, showing how data-driven precision oncology shapes personalized cancer care worldwide.

Teclistamab-based induction yielded a 100% overall response rate in transplant-eligible newly diagnosed multiple myeloma in the phase 2 MajesTEC-5 trial.

The FDA has accepted a BLA resubmission for RP1 plus nivolumab for patients with advanced melanoma.

Matthew Matasar, MD, discussed standout lymphoma readouts from ASCO and EHA 2026, including the frontMIND trial and emerging bispecific antibody regimens.

In 1153 women undergoing breast imaging and NCB, BIRADS 5 status, symptomatic presentation, and age over 70 years were associated with shorter time to biopsy, while socioeconomic and demographic factors were not significant predictors of delay.

In a retrospective multi-institution study of 267 early-stage breast cancer patients, the TumorSight Viz AI algorithm achieved landmark identification and measurement accuracy comparable to inter-radiologist variability, generating results in an average of 8 minutes per patient.

The CHMP recommended pirtobrutinib in chronic lymphocytic leukemia based on data from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.

The first reported case of xanthogranulomatous mastitis in a pregnant patient was managed conservatively, avoiding surgery during pregnancy; a literature review of 24 cases found co-incidence of malignancy in 14% of excised lesions.

Routine intraoperative frozen section analysis of sentinel lymph nodes after neoadjuvant chemotherapy did not improve surgical outcomes and led to unnecessary axillary lymph node dissection in over half of intraoperatively positive cases.

Steven K. Libutti, MD, FACS, discussed the amenities that make the new Melchiorre Cancer Center a warm and welcoming facility for patients.

ASCO Breakthrough 2026 spotlights AI-driven tumor boards, trial matching, and MRD/ctDNA-guided therapy, signaling faster and more personalized cancer care.

In this prospective multicenter study, the next-generation MarginProbe device (MP2) achieved sensitivity of 76.8% and specificity of 49.1% for intraoperative lumpectomy margin assessment, meeting all predefined success criteria and earning FDA approval in September 2025.

Therapeutic mammoplasty with contralateral symmetrization showed low long-term local recurrence in early breast cancer, with failure to complete adjuvant therapy as the strongest modifiable predictor of recurrence.

Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG3 can reverse checkpoint inhibitor resistance.

ASCO Breakthrough 2026 spotlights ADCs, CAR-T, ctDNA-guided colorectal care and menin inhibitors driving precision cancer treatment.

Experts map DLBCL CAR‑T from early referral and bridging therapy to managing CRS, ICANS, and survivorship challenges in community practice.

The tentative approval covers enzalutamide tablets in 4 doses—40 mg, 80 mg, 120 mg, and 160 mg—as a generic equivalent to the reference product.

The CHMP’s recommendation for approving teclistamab plus daratumumab in this multiple myeloma population is based on data from the phase 3 MajesTEC-3 study.

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.